Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis

RT @dbdugger: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An…

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/FDT03p23Pr

RT @dbdugger: Have other drug classes within Gilead's portfolio been investigated? Yes, the integrase inhibitor. Quinolines-Based SARS-CoV-…

Have other drug classes within Gilead's portfolio been investigated? Yes, the integrase inhibitor. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.c

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/FDT03p23Pr

RT @dbdugger: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An…

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/FDT03p23Pr

RT @dbdugger: Name: Elvitegravir Class: Integrase Inhibitor Found In: Stribild, Genvoya Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibit…

Name: Elvitegravir Class: Integrase Inhibitor Found In: Stribild, Genvoya Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/FDT03p23Pr

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis https://t.co/w41tRWbdS3

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

RT @dbdugger: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An…

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

Elvitegravir, an integrase inhibitor. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

RT @dbdugger: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An…

RT @dbdugger: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An…

RT @dbdugger: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An…

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

@mviktoro Yes. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

This article was published July, 2020. https://t.co/w41tRWbLHB

@AlixBurack Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

RT @dbdugger: There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWb…

RT @dbdugger: There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWb…

RT @dbdugger: There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWb…

RT @dbdugger: There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWb…

RT @dbdugger: There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWb…

RT @dbdugger: There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWb…

There are a number of drugs in Gilead's portfolio that could have been trialed close to three years ago. https://t.co/w41tRWbdS3

RT @dbdugger: @dianaberrent Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Agains…

@dianaberrent Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

@ShitterSecurity @Parsifaler https://t.co/InVrtHtyxM https://t.co/QYvespcaxX https://t.co/qwph6C8ZAy Azvudine is another one with great potential for damage mitigation against the virus/genetic therapies. https://t.co/3Y35b8of9D https://t.co/zU0IK5bPch

@LongCovid1997 Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbdS3

@LettersfromTim @riceparktrees https://t.co/w41tRWbdS3

@davideyoungmd @sashayoungr @AlisaValdesRod1 https://t.co/w41tRWbLHB https://t.co/zguYXkRzuW https://t.co/HdYttTmdF4 https://t.co/HdYttTmdF4 https://t.co/gxrC2WmYQZ https://t.co/AqlB0008xb https://t.co/AqlB0008xb https://t.co/YKRCmOBtLS

RT @dbdugger: Let's look at the literature. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-R…

RT @dbdugger: Let's look at the literature. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-R…

RT @dbdugger: Let's look at the literature. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-R…

RT @dbdugger: Let's look at the literature. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-R…

Let's look at the literature. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. https://t.co/w41tRWbLHB

RT @ChristosArgyrop: @persistingvirus @dbdugger @pfizer @POTUS @TheDemocrats @VP @CNN @CBSNews @NBCNews @WKRN @WSMV @NC5 Daniel is referrin…

@persistingvirus @dbdugger @pfizer @POTUS @TheDemocrats @VP @CNN @CBSNews @NBCNews @WKRN @WSMV @NC5 Daniel is referring to this paper https://t.co/QMI6kVbJ42 Interestingly enough saquinavir , a very old PI that is off patent and no longer manufactured (I t

@KathieKaneW @nkondracki @WesElyMD I have been watching for studies in which 1st live HIV meds have been investigated. Here is one such study in which elvitegravir showed potential. It is contained in Stribild, Genvoya and alone. It is manufactured by Gile

@DrKatrin_Rabiei @Wikipedia PreP lacks elvitegravir, which is found in Stribild and Genvoya. This paper suggests it can bind. https://t.co/r7WfO0zHcs

RT @FoolsMultiply: @edgar_a_bitch The result shows rilapladib is the only #quinoline that can interrupt the #Spike-RBD-ACE2 complex. #SARSC…

@edgar_a_bitch The result shows rilapladib is the only #quinoline that can interrupt the #Spike-RBD-ACE2 complex. #SARSCoV2 #COVID19 . #Q498Y #Staphyloccus #pneumonia https://t.co/NhZWKNlqn4

@BioInorgChem_UW @SebVidalChem @DyylaanL @ChemRxiv @CapciAysun @ia_yaremenko @aztul @alterex2013 We did not measure 3CLpro/Mpro inhibition (can be done in a new/further collaboration only). Molecular docking approach / structure-based virtual screening of

RT @FrontMicrobiol: New Research: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing…

Frontiers | Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis | Microbiology https://t.co/t1dUkpmcI7

RT @FrontMicrobiol: New Research: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing…

New Research: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis https://t.co/gwqRZMfP0k #microbiology

@Suriya_offl Happy birthday Thalaiva 😍😍😍 Hereby, i indeed happy to share this, my research on COVID-19 has been published in the esteemed journal 'Frontiers in Microbiology' on that day of @Suriya_offl anna Birthday.... https://t.co/XahHjYhQuR

RT @RandyMyself: My article is featured on the @ResearchGate #COVID19 community page. Read it here: https://t.co/f9Vrdnpda5